New drug could protect against nuclear radiation exposure

New drug could protect against nuclear radiation exposure

7:14 AM, 26th January 2015
New drug could protect against nuclear radiation exposure
Gabor Tigyi, Professor, University of Tennessee Health Science Center. (C) Elsevier

TENNESSEE, US: The 2011 Fukushima disaster was a stark reminder of the continuing dangers posed by nuclear fallout, highlighting the need for an approved drug that can be taken after radiation exposure to protect against organ injury and death.

A study published by Cell Press in Chemistry & Biology identifies a drug candidate called DBIBB that increases the survival of mice suffering from radiation syndrome, even when treatment started three days after radiation exposure. The findings suggest that DBIBB shows promise for becoming the first drug capable of treating acute radiation syndrome caused by the high levels of radiation released by nuclear explosions.

“The 21st Century has presented humankind with unforeseen challenges, including the possibility of radiation terrorism. We hope that the scientific community and our efforts will provide protection through medical countermeasures against the harmful effects of ionizing radiation and also help humans to benefit from the useful effects of nuclear technology,” said Gabor Tigyi, Professor, University of Tennessee Health Science Center (UTHSC).

Nuclear explosions can expose humans to high levels of ionizing radiation, which can cause cell death and organ injury due to DNA damage. Although some agents tested by the military can provide some protection against radiation sickness when taken prior to radiation exposure, no approved drug is effective when taken after radiation exposure.

In previous studies, Tigyi and his collaborators found that a molecule called lysophosphatidic acid (LPA), which is naturally generated during the course of blood clotting, activates the LPA2 receptor to protect against radiation-induced cell death. The researchers also previously identified an LPA-like compound that protected mice from radiation-induced death, but it did not specifically target the LPA2 receptor or possess the desired drug-like potency required for clinical use.

To overcome this hurdle, Tigyi and his team developed a computational model of the LPA2 binding site and refined their previously identified compound into a more potent and specific activator of the LPA2 receptor, which is abundantly expressed in the most radiation-sensitive types of cells in mammalian tissues. The resulting compound, called DBIBB, protected mouse embryonic skin cells from radiation-induced DNA damage and enhanced the survival of radiation-exposed blood cells, intestinal cells, and other types of cells from mice and humans. Moreover, 93 per cent of mice that were treated with DBIBB three days after radiation exposure remained alive 30 days later, compared with only 20 per cent of mice that were not treated with the drug candidate.

This promising compound will soon join the regulatory pipeline of a biotech company called RxBio Inc., which was cofounded by Tigyi and other UTHSC faculty. “Humankind might soon have a defense against unintended radiation exposure. This technology can potentially also help cancer patients from the side effects of radiation therapy and astronauts from chronic exposure to cosmic rays on their journey to Mars,” said Tigyi.

 

© EurekAlert News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Sigma-Aldrich, VIB collaborate to provide translational research technologies

ST LOUIS, US: Sigma-Aldrich Corporation’s Research business unit, an industry leader in supporting translational researchers by supplying the pr ...

Read more
Sika to acquire Axson Technologies

BAAR, SWITZERLAND: Sika has entered into exclusive negotiations with Axson management and shareholders to acquire Axson Technologies, a leader in the ...

Read more
Ten new antibodies developed in battle against cancer

AARHUS, DENMARK: Researchers from Aarhus University in Denmark have developed ten new antibodies that can be used in the battle against cancer. These ...

Read more
Matheson to supply oxygen, nitrogen to Sasol ethane cracker in Louisiana, US

BASKING RIDGE, US: Matheson has entered into an agreement with Sasol to supply tonnage oxygen and nitrogen to Sasol’s world-scale ethane cracker ...

Read more
BASF to invest €56 million in polyvinylpyrrolidone expansion

LUDWIGSHAFEN, GERMANY: BASF plans to invest up to €56 million in the expansion of its polyvinylpyrrolidone (PVP) value chain over the next four y ...

Read more
Self-cleaning, self-powered smart keyboard identifies computer users

WASHINGTON DC, US: In a novel twist in cybersecurity, scientists have developed a self-cleaning, self-powered smart keyboard that can identify compute ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X